3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Virus Diseases
1
Tumor Virus Infections
1
Squamous Cell Carcinoma of Head and Neck
1
Pharyngeal Diseases
1
Papillomavirus Infections
1
Otorhinolaryngologic Neoplasms
1
Otorhinolaryngologic Diseases
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Head and Neck Neoplasms
1
DNA Virus Infections
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Interventions
fludarabine
4
Cyclophosphamide
4
Cisplatin
4
pembrolizumab
3
atezolizumab
3
Pemetrexed
3
fludarabine phosphate
2
entrectinib
2
durvalumab
2
cobimetinib
2
capmatinib
2
alectinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Paclitaxel
2
Nivolumab
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Busulfan
2
130-nm albumin-bound paclitaxel
2
trametinib
1
spartalizumab
1
ruxolitinib
1
repotrectinib
1
pralsetinib
1
ponatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
Nimorazole
×
1 year
×
Clear all
NCT04124198
2025-12-31
QoLATI
Rigshospitalet, Denmark
Phase NA
Active not recruiting
138 enrolled